Sai Life Sciences

Sai Life Sciences

922.30
-0.80
(-0.09%)
hide
Key Fundamentals
Add Ratio
Market Cap
19,299.10 Cr
EPS
8.83
PE Ratio
79.42
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
943.00
52 Week Low
636.10
PB Ratio
9.11
Debt to Equity
0.41
Analyst Rating and Forecast
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
Sai Life Sciences reported consolidated net profit of 838 million rupees for Q2, representing a significant increase from 415 million rupees in the same quarter last year. The company's revenue also grew substantially to 5.4 billion rupees compared to 3.95 billion rupees year-on-year. The results show strong financial performance across both profitability and revenue metrics.
positive
Sai Life Sciences Limited has allotted 2,49,969 fully paid-up equity shares of Re. 1 each following the exercise of stock options under two employee plans. The allotment includes 19,995 shares under ESOP 2008 at an exercise price of Rs. 188.90 per share and 2,29,974 shares under MESOP 2018 at exercise prices of Rs. 23.30 and Rs. 127.30 per share for different tranches. The Board of Directors approved the allotment through a circular resolution dated November 4, 2025. Following this allotment, the company's total issued share capital stands at 210,171,761 shares. The ESOP plans are designed to attract, retain and reward employees with a maximum vesting period of 5 years.
positive
Sai Life Sciences Limited announced the groundbreaking of a new CMC Process R&D Center at its integrated R&D campus in Hyderabad. The facility is expected to be operational by September 2026 and will double the company's Process R&D capacity. The new center will span 100,000 sq. ft. across five floors and include 140 process chemistry fume hoods, dedicated laboratories for peptides and oligo intermediates & linkers, a 25,000 sq. ft. centralized analytical laboratory, and early-phase clinical supply capabilities. The facility will introduce new capabilities in peptide development, oligo intermediates & linkers, formulation development, and early-phase clinical supplies. The investment is part of the company's planned capital expenditure, driven by increasing demand for late-stage development programs and scalable CMC capacity. CEO Krishna Kanumuri stated the expansion aims to enhance the company's ability to combine scientific excellence with execution agility as partners seek greater speed and flexibility.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,685.90
#1 4,05,487.60
38.58
#1 54,729.00
9.71
#1 10,980
2.89
54.39
6,883.50
1,80,638.10
79.27
9,712.00
18.67
2,191
26.74
74.24
1,501.50
1,21,429.70
22.30
28,409.50
7.12
5,291
3.71
39.79
3,553.40
1,20,994.20
60.08
11,539.40
6.99
1,911
19.91
46.89
1,205.20
1,00,153.70
#1 17.53
33,741.20
16.73
5,725
-0.38
36.98
2,309.10
97,803.10
49.83
12,744.20
#1 20.90
2,007
-21.05
28.96
936.70
97,775.80
20.00
23,511.00
18.55
4,615
34.60
30.29
1,955.50
89,318.30
24.00
22,909.50
13.74
3,306
#1 72.75
50.08
5,643.50
67,721.60
28.92
13,458.30
3.70
2,216
21.39
62.15
1,140.60
66,739.90
19.54
32,345.60
9.43
3,484
3.81
59.80

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
15.86 %
Net Income Growth
105.43 %
Cash Flow Change
19.37 %
ROE
-5.89 %
ROCE
-1.49 %
EBITDA Margin (Avg.)
21.38 %

Quarterly Financial Results

Quarterly Financials
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
395
443
288
406
449
589
506
553
Expenses
287
315
254
293
320
422
376
392
EBITDA
108
128
34
112
129
167
131
161
Operating Profit %
25 %
28 %
9 %
26 %
27 %
27 %
24 %
27 %
Depreciation
31
31
31
36
34
38
38
40
Interest
23
21
21
21
23
11
12
9
Profit Before Tax
53
76
-18
55
72
119
81
112
Tax
13
20
-5
14
18
31
20
28
Net Profit
40
56
-14
42
54
88
61
84
EPS in ₹
2.19
31.00
-0.74
2.22
2.89
4.24
2.90
4.01

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
Total Assets
1,410
1,817
2,157
2,187
2,275
3,160
Fixed Assets
641
753
751
1,037
1,180
1,488
Current Assets
613
804
944
964
945
1,505
Capital Work in Progress
91
194
410
151
107
125
Investments
0
0
0
2
2
2
Other Assets
679
870
997
997
987
1,545
Total Liabilities
1,410
1,817
2,157
2,187
2,275
3,160
Current Liabilities
467
599
713
759
740
733
Non Current Liabilities
149
356
565
540
560
299
Total Equity
794
863
879
888
975
2,128
Reserve & Surplus
777
845
861
870
957
2,108
Share Capital
16
18
18
18
18
21

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
239
-150
-1
75
-80
-24
79
Investing Activities
-158
-262
-260
-102
-99
-191
-536
Operating Activities
129
116
-36
105
219
263
314
Financing Activities
268
-4
296
72
-201
-95
301

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
39.64 %
35.24 %
35.24 %
35.17 %
35.15 %
34.93 %
FIIs
0.00 %
7.64 %
11.72 %
12.36 %
14.58 %
22.49 %
DIIs
0.00 %
5.61 %
11.95 %
13.26 %
21.64 %
29.94 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
18.68 %
8.88 %
7.69 %
6.56 %
7.90 %
Others
60.36 %
32.84 %
32.22 %
31.52 %
22.07 %
4.74 %
No of Share Holders
70
5,72,970
82
1,40,677
1,26,380
1,19,704

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
06 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Nov 2025 892.85 923.20
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 695.75 694.80
13 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 May 2025 717.70 713.35
07 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Aug 2025 815.20 792.85
11 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
11 Sept 2025 791.55 861.70

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release4 hours ago
Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended On 30 September 20256 hours ago
Board Meeting Outcome for For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended On 30 September 20256 hours ago
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS2 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 24, 2025
Board Meeting Intimation for Consideration And Approval Of Un-Audited Financial Results (Standalone And Consolidated) For The Quarter Ended 30 September 2025.Oct 24, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 17, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Oct 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Closure of Trading WindowSep 29, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 17, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 15, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 11, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 11, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 11, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 03, 2025
Corrigendum To The Notice Of The 26Th Annual General Meeting.Sep 03, 2025
Company -UpdatesSep 03, 2025
Company-UpdatesSep 02, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 30, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 28, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 23, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 19, 2025
Reg. 34 (1) Annual Report.Aug 18, 2025
Notice Of 26Th Annual General Meeting Of The Members Of Sai Life Sciences Limited To Be Held On Thursday 11Th September 2025 At 10.30 A.M. (IST)Aug 18, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 18, 2025
Announcement under Regulation 30 (LODR)-Credit RatingAug 14, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 08, 2025
Announcement under Regulation 30 (LODR)-Meeting UpdatesAug 08, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 08, 2025
Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended On 30 June 2025.Aug 07, 2025
Board Meeting Outcome for Board Meeting Outcome For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended On 30 June 2025Aug 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 23, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 23, 2025
Board Meeting Intimation for Notice Of The Board MeetingJul 21, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jul 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Clarification On Increase In VolumeJul 03, 2025
Clarification sought from Sai Life Sciences LtdJul 03, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Nippon India Small Cap Fund Direct- Growth
0.00%
-5772731
-0.75%
-0.73%
Invesco India Smallcap Fund Direct - Growth
0.00%
-4942410
-5.28%
-5.28%
Invesco India Large & Mid Cap Fund Direct-Growth
0.00%
-4283799
-4.37%
-4.35%
Axis Small Cap Fund Direct-Growth
0.00%
-3771187
-1.25%
-1.22%
Nippon India Multi Cap Fund Direct-Growth
0.00%
-3242351
-0.59%
-0.63%
Invesco India Mid Cap Fund Direct-Growth
0.00%
-3234498
-3.27%
-3.31%
Nippon India Pharma Fund Direct-Growth
0.00%
-2555745
-2.71%
-2.52%
HSBC Small Cap Fund Direct-Growth
0.00%
-2310256
-1.24%
-0.95%
DSP Healthcare Fund Direct - Growth
0.00%
-1703020
-4.77%
-4.52%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
0.00%
-1225785
-2.16%
-2.10%
Invesco India Flexi Cap Fund Direct - Growth
0.00%
-1175306
-2.53%
-1.93%
Axis Flexi Cap Fund Direct-Growth
0.00%
-1121521
-0.75%
-0.72%
Aditya Birla Sun Life Flexi Cap Fund Direct-Growth
0.00%
-1100000
-0.41%
-0.40%
Mahindra Manulife Multi Cap Fund Direct - Growth
0.00%
-1070000
-1.61%
-1.57%
Invesco India Multicap Fund Direct-Growth
0.00%
-979908
-2.07%
-1.83%
Axis Multicap Fund Direct-Growth
0.00%
-811956
-0.81%
-0.80%
Mirae Asset Healthcare Fund Direct - Growth
0.00%
-786462
-2.45%
-2.22%
HSBC Multi Cap Fund Direct - Growth
0.00%
-753650
-1.29%
-1.26%
Aditya Birla Sun Life ELSS Tax Saver Direct-Growth
0.00%
-692521
-0.39%
-0.38%
Aditya Birla Sun Life Multi-Cap Fund Direct-Growth
0.00%
-656395
-0.87%
-0.84%
HSBC Large and Mid Cap Fund Direct - Growth
0.00%
-597062
-1.16%
-1.14%
HDFC Multi Cap Fund Direct - Growth
0.00%
-577771
-0.27%
-0.26%
Bandhan Large & Mid Cap Fund Direct-Growth
0.00%
-546674
-0.43%
-0.44%
Nippon India Balanced Advantage Fund Direct-Growth
0.00%
-532500
-0.48%
-0.47%
Aditya Birla Sun Life Balanced Advantage Fund Direct-Growth
0.00%
-515512
-0.53%
-0.52%

Technical Indicators

RSI(14)
Neutral
63.39
ATR(14)
Volatile
23.13
STOCH(9,6)
Overbought
80.26
STOCH RSI(14)
Overbought
98.19
MACD(12,26)
Bullish
4.83
ADX(14)
Strong Trend
25.22
UO(9)
Bearish
48.47
ROC(12)
Uptrend And Accelerating
4.89
WillR(14)
Overbought
-18.68